Peptide Database

CJC-1295 with DAC · DAC:GRF

CJC-1295 is a modified GHRH analog with a Drug Affinity Complex (DAC) that binds to serum albumin, dramatically extending its half-life compared to native GHRH. It produces sustained elevation of GH and IGF-1 levels over days rather than hours. Research focuses on body composition improvements, muscle growth, and fat loss through prolonged GH axis stimulation.

C₁₅₂H₂₅₂N₄₂O₄₂S · 3647.28 Da

Growth Hormone-Releasing Hormone · Somatoliberin

GHRH is the endogenous 44-amino-acid hypothalamic peptide that drives the pulsatile secretion of growth hormone from the anterior pituitary. Native GHRH acts through GHRHR, stimulating GH gene transcription and secretion. It has a very short half-life in vivo, making it impractical as a therapeutic — which drove the development of modified analogs like sermorelin, CJC-1295, and tesamorelin. Research into GHRH receptor signaling underpins the entire GH secretagogue drug class.

CJC-1295 without DAC · Modified GRF 1-29

Mod GRF 1-29 is a modified version of GHRH(1-29) with four amino acid substitutions that increase stability and half-life without the DAC albumin-binding component. It produces a natural, pulsatile GH release and is commonly paired with GHRPs (like Ipamorelin) for a synergistic GH pulse. Its shorter duration preserves natural pituitary feedback mechanisms.